Identification of a new chemical class of antimalarials

Journal of Infectious Diseases

Volumn 206, Issue 5, 2012, Pages 735-743

  Brunner, Ralf ^a,b   Aissaoui, Hamed ^c   Boss, Christoph ^c   Bozdech, Zbynek ^d   Brun, Reto ^a,b   Corminboeuf, Olivier ^c   Delahaye, Stephane ^c   Fischli, Christoph ^a,b   Heidmann, Bibia ^c   Kaiser, Marcel ^a,b   Kamber, Jolanda ^a,b   Meyer, Solange ^c   Papastogiannidis, Petros ^a,b   Siegrist, Romain ^c   Voss, Till ^a,b   Welford, Richard ^c   Wittlin, Sergio ^a,b   Binkert, Christoph ^c  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c ACTELION PHARMACEUTICALS LTD   (Switzerland)

^d NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ACT 213615; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ARTESUNATE; CHLOROQUINE; PYRIMETHAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; GROWTH INHIBITION; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALARIA FALCIPARUM; MICROARRAY ANALYSIS; MICROBIAL GROWTH; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMODIUM BERGHEI; PLASMODIUM BERGHEI INFECTION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ANIMALS; ANTIMALARIALS; BIOLOGICAL AVAILABILITY; CELL LINE; ERYTHROCYTES; INHIBITORY CONCENTRATION 50; MALARIA; MICE; PARASITEMIA; PIPERAZINES; PLASMODIUM BERGHEI; RATS;

EID: 84864955346     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis418     Document Type: Article

References (43)

1. World Health Organization (WHO). Malaria factsheet no. 94. Geneva: WHO, 2010.
2. Tuteja R. Malaria -an overview. FEBS J 2007; 274:4670-9.
3. Laxminarayan R, Parry IWH, Smith DL, Klein EY. Should new antimalarial drugs be subsidized? J Health Econ 2010; 29:445-56.
4. Wongsrichanalai C, Meshnick SR. Declining artesunate-mefloquine efficacy against falciparum malaria on the Cambodia-Thailand border. Emerg Infect Dis 2008; 14:716-9. (Pubitemid 351838633)
5. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455-67.
6. Dondorp AM, Yeung S, White L, et al. Artemisinin resistance: current status and scenarios for containment. Nat Rev Micro 2010; 8:272-80.
7. Enserink M. Malaria's drug miracle in danger. Science 2010; 328:844-6.
8. Fidock DA. Drug discovery: priming the antimalarial pipeline. Nature 2010; 465:297-8.
9. Okie S. A new attack on malaria. N Engl J Med 2008; 358:2425-8. (Pubitemid 351793015)
10. Olliaro P, Wells T. The global portfolio of new antimalarial medicines under development. Clin Pharmacol Ther 2009; 85:584-95.
11. Wells TNC, Alonso PL, Gutteridge WE. New medicines to improve control and contribute to the eradication of malaria. Nat Rev Drug Discov 2009; 8:879-91.
12. MMV. Science portfolio, medicines for malaria venture, Geneva. 2011. http://www.mmv.org/research-development/science-portfolio. Accessed 20 January 2012.
13. Plouffe D, Brinker A, McNamara C, et al. In silico activity profiling reveals the mechanism of action of antimalarials discovered in a highthroughput screen. Proc Natl Acad Sci USA 2008; 105:9059-64.
14. Gamo F-J, Sanz LM, Vidal J, et al. Thousands of chemical starting points for antimalarial lead identification. Nature 2010; 465:305-10.
15. Guiguemde WA, Shelat AA, Bouck D, et al. Chemical genetics of Plasmodium falciparum. Nature 2010; 465:311-5.
16. Meister S, Plouffe DM, Kuhen KL, et al. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science 2011; 334:1372-7.
17. Rottmann M, McNamara C, Yeung BKS, et al. Spiroindolones, a potent compound class for the treatment of malaria. Science 2010; 329:1175-80.
18. Charman SA, Arbe-Barnes S, Bathurst IC, et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci U S A 2011; 108:4400-5.
19. Booker ML, Bastos CM, Kramer ML, et al. Novel inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in the mouse model. J Biol Chem 2010; 285:33054-64.
20. Coteron JM, Marco M, Esquivias J, et al. Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate sehydrogenase inhibitors with clinical candidate potential. J Med Chem 2011; 54:5540-61.
21. Coombs GH, Goldberg DE, Klemba M, Berry C, Kay J, Mottram JC. Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. Trends Parasitol 2001; 17:532-7. (Pubitemid 34185360)
22. Ersmark K, Samuelsson B, Hallberg A. Plasmepsins as potential targets for new antimalarial therapy. Med Res Rev 2006; 26:626-66. (Pubitemid 44230415)
23. Boss C, Richard-Bildstein S, Weller T, Fischli W, Meyer S, Binkert C. Inhibitors of the Plasmodium falciparum parasite aspartic protease plasmepsin II as potential antimalarial agents. Curr Med Chem 2003; 10:883-907. (Pubitemid 36582237)
24. Corminboeuf O, Dunet G, Hafsi M, et al. Inhibitors of plasmepsin II-potential antimalarial agents. Bioorg Med Chem Lett 2006; 16:6194-9. (Pubitemid 44709913)
25. Boss C, Corminboeuf O, Grisostomi C, et al. Achiral, cheap, and potent inhibitors of plasmepsins I, II, and IV. Chem Med Chem 2006; 1:1341-5.
26. Bonilla JA, Bonilla TD, Yowell CA, Fujioka H, Dame JB. Critical roles for the digestive vacuole plasmepsins of Plasmodium falciparum in vacuolar function. Mol Microbiol 2007; 65:64-75. (Pubitemid 46934483)
27. Moura PA, Dame JB, Fidock DA. Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors. Antimicrob Agents Chemother 2009; 53:4968-78.
28. White NJ. Qinghaosu (artemisinin): the price of success. Science 2008; 320:330-4. (Pubitemid 351555649)
29. Jiménez-Díaz MB, Mulet T, Viera S, et al. Improved murine model of malaria using Plasmodium falciparum competent strains and nonmyelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes. Antimicrob Agents Chemother 2009; 53:4533-6.
30. Trager W, Jensen JB. Human malaria parasites in continuous culture. Science 1976; 193:673-5.
31. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother 1979; 16:710-8. (Pubitemid 10082023)
32. Hofer S, Brun R, Maerki S, Matile H, Scheurer C, Wittlin S. In vitro assessment of the pharmacodynamic properties of DB75, piperaquine, OZ277 and OZ401 in cultures of Plasmodium falciparum. J Antimicrob Chemother 2008; 62:1061-4.
33. Regalado EL, Tasdemir D, Kaiser M, Cachet N, Amade P, Thomas OP. Antiprotozoal steroidal saponins from the marine sponge Pandaros acanthifolium. J Nat Prod 2010; 73:1404-10.
34. Vennerstrom JL, Arbe-Barnes S, Brun R, et al. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 2004; 430:900-4. (Pubitemid 39119218)
35. ter Kuile F, White NJ, Holloway P, Pasvol G, Krishna S. Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol 1993; 76:85-95. (Pubitemid 23197907)
36. Maerki S, Brun R, Charman SA, Dorn A, Matile H, Wittlin S. In vitro assessment of the pharmacodynamic properties and the partitioning of OZ277/RBx-11160 in cultures of Plasmodium falciparum. J Antimicrob Chemother 2006; 58:52-8. (Pubitemid 44294987)
37. Dieckmann A, Jung A. Stage-specific sensitivity of Plasmodium falciparum to antifolates. Z Parasitenkd 1986; 72:591-4. (Pubitemid 17192302)
38. Hu G, Cabrera A, Kono M, et al. Transcriptional profiling of growth perturbations of the human malaria parasite Plasmodium falciparum. Nat Biotechnol 2010; 28:91-8.
39. White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997; 41:1413-22. (Pubitemid 27289660)
40. White NJ. Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia 1999; 41:301-8.
41. MMV. Strategy for the selection and early development of combination drugs for the treatment of uncomplicated P. falciparum malaria. Geneva: Medicines for Malaria Venture, 2010. http://www. mmv.org/sites/default/files/ uploads/docs/essential-info-for-scientists/Strategy-for-the-selection-and-early- development-of-combination-drugs-2010.pdf. Accessed 11 August 2011.
42. Gunasekera AM, Myrick A, Le Roch K, Winzeler E, Wirth DF. Plasmodium falciparum: genome wide perturbations in transcript profiles among mixed stage cultures after chloroquine treatment. Exp Parasitol 2007; 117:87-92. (Pubitemid 47102295)
43. Ganesan K, Ponmee N, Jiang L, et al. A genetically hard-wired metabolic transcriptome in Plasmodium falciparum fails to mount protective responses to lethal antifolates. PLoS Pathog 2008; 4: e1000214.